首页> 外文期刊>BMC Nephrology >A case of lipoprotein glomerulopathy with thrombotic microangiopathy due to malignant hypertension
【24h】

A case of lipoprotein glomerulopathy with thrombotic microangiopathy due to malignant hypertension

机译:恶性高血压引起的脂蛋白性肾小球病合并血栓性微血管病1例

获取原文
       

摘要

Background Lipoprotein glomerulopathy (LPG) is a rare inherited renal disease characterized by intraglomerular lipoprotein within the lumina of severely dilated glomerular capillaries. The common clinical presentation of LPG includes proteinuria or nephrotic syndrome. Hypertension and anemia were thought to be mild in LPG. Thrombotic microangiopathy (TMA) in LPG has not been previously reported. In this report, we present a patient with LPG that developed TMA. To the best of our knowledge, this is the first report of TMA in LPG. Case presentation Four years ago (2005), a 19-year-old Chinese woman was diagnosed with nephrotic syndrome and provided prednisone treatment. A combination of prednisone and cyclophosphamide did not have any effect and was discontinued after six months. Although she was steroid-resistant, over the next subsequent three years, she maintained normal renal function without anemia and thrombocytopenia. In February 2009, she had a severe headache and blurry vision and presented at a local hospital with severe hypertension. Blood pressure was 220/160?mmHg. Laboratory data showed hemoglobin 3.8?g/dL; platelet counts 29×109/L; urinary protein 7.90?g/d; total bilirubin 29.9 umol/L; indirect bilirubin 28.2 umol/L; LDH 1172 U/L; ALB 2.66?g/dL; urea nitrogen 52?mg/dL; serum creatinine 3.2?mg/dL; triglyceride 253?mg/dL; total cholesterol 273?mg/dL. ANA, ds-DNA, ANCA, anti-GBM antibody and anticardiolipin were all negative. A renal biopsy revealed LPG with TMA. Genetic evaluation showed the patient carried the APOE Kyoto mutation. Adequate control of blood pressure improved microangiopathic anemia and thrombocytopenia, however, renal function did not improve and she eventually developed uremia and became hemodialysis dependent. Conclusion We report on a rare case of TMA probably due to malignant hypertension in LPG. Early lipid-lowering and antihypertensive treatment may improve outcome. The pathophysiologic relationship between LPG and TMA should be investigated further.
机译:背景脂蛋白肾小球病(LPG)是一种罕见的遗传性肾脏疾病,其特征是严重扩张的肾小球毛细血管腔内的肾小球内脂蛋白。 LPG的常见临床表现包括蛋白尿或肾病综合征。 LPG的高血压和贫血被认为是轻度的。 LPG中的血栓性微血管病(TMA)以前尚未见报道。在本报告中,我们介绍了患有TMA的LPG患者。据我们所知,这是TMA在LPG中的第一份报告。病例介绍四年前(2005年),一名19岁的中国妇女被诊断出患有肾病综合征并提供了泼尼松治疗。泼尼松和环磷酰胺的组合没有任何作用,六个月后停用。尽管她对类固醇耐药,但在随后的三年中,她保持了正常的肾功能,没有贫血和血小板减少症。 2009年2月,她患有严重的头痛和视力模糊,并在当地一家患有严重高血压的医院就诊。血压为220/160?mmHg。实验室数据显示血红蛋白为3.8?g / dL;血小板计数29×10 9 / L;尿蛋白7.90?g / d;总胆红素29.9 umol / L;间接胆红素28.2 umol / L; LDH 1172 U / L; ALB 2.66?g / dL;尿素氮52?mg / dL;血清肌酐3.2?mg / dL;甘油三酸酯253?mg / dL;总胆固醇273?mg / dL。 ANA,ds-DNA,ANCA,抗GBM抗体和抗心磷脂均阴性。肾脏活检显示有TMA的LPG。遗传评估显示该患者携带APOE Kyoto突变。适当控制血压可改善微血管性贫血和血小板减少症,但是肾功能并未改善,她最终发展为尿毒症并成为血液透析依赖者。结论我们报告了一例罕见的TMA病例,可能是由于LPG恶性高血压所致。早期的降脂和降压治疗可以改善预后。 LPG与TMA之间的病理生理关系应进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号